JP7086942B2 - Gpr120モジュレーターとして有用な単環式化合物 - Google Patents

Gpr120モジュレーターとして有用な単環式化合物 Download PDF

Info

Publication number
JP7086942B2
JP7086942B2 JP2019513935A JP2019513935A JP7086942B2 JP 7086942 B2 JP7086942 B2 JP 7086942B2 JP 2019513935 A JP2019513935 A JP 2019513935A JP 2019513935 A JP2019513935 A JP 2019513935A JP 7086942 B2 JP7086942 B2 JP 7086942B2
Authority
JP
Japan
Prior art keywords
compound
lcms
esi
nmr
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019513935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530674A5 (enExample
JP2019530674A (ja
Inventor
ブライアン ライムンド,
エレナ エス. コルタン,
ジョン グリフィン,
エリック ステインジェランド,
Original Assignee
インテグラル ヘルス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インテグラル ヘルス, インコーポレイテッド filed Critical インテグラル ヘルス, インコーポレイテッド
Publication of JP2019530674A publication Critical patent/JP2019530674A/ja
Publication of JP2019530674A5 publication Critical patent/JP2019530674A5/ja
Application granted granted Critical
Publication of JP7086942B2 publication Critical patent/JP7086942B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019513935A 2016-09-12 2017-09-11 Gpr120モジュレーターとして有用な単環式化合物 Active JP7086942B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662393616P 2016-09-12 2016-09-12
US62/393,616 2016-09-12
PCT/US2017/050956 WO2018049324A1 (en) 2016-09-12 2017-09-11 Monocyclic compounds useful as gpr120 modulators

Publications (3)

Publication Number Publication Date
JP2019530674A JP2019530674A (ja) 2019-10-24
JP2019530674A5 JP2019530674A5 (enExample) 2020-11-12
JP7086942B2 true JP7086942B2 (ja) 2022-06-20

Family

ID=61562455

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019513935A Active JP7086942B2 (ja) 2016-09-12 2017-09-11 Gpr120モジュレーターとして有用な単環式化合物

Country Status (7)

Country Link
US (3) US10800773B2 (enExample)
EP (1) EP3509587B1 (enExample)
JP (1) JP7086942B2 (enExample)
KR (1) KR102537985B1 (enExample)
CN (1) CN110225752B (enExample)
CA (1) CA3041033A1 (enExample)
WO (1) WO2018049324A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7086942B2 (ja) 2016-09-12 2022-06-20 インテグラル ヘルス, インコーポレイテッド Gpr120モジュレーターとして有用な単環式化合物
CA3041038A1 (en) * 2016-09-12 2018-03-15 Numerate, Inc. Bicyclic compounds useful as gpr120 modulators
AU2019255363A1 (en) * 2018-04-20 2020-11-05 Krish Biotech Research Private Limited Method of treatment of non-alcoholic steatohepatitis, nash
US11142525B2 (en) * 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
EP4143186A1 (en) 2020-05-01 2023-03-08 Pfizer Inc. Azalactam compounds as hpk1 inhibitors
KR20230022457A (ko) * 2020-05-08 2023-02-15 조지아뮨 엘엘씨 Akt3 조절제
CN114671827B (zh) * 2020-12-24 2024-09-20 杭州百新生物医药科技有限公司 邻苯甲酰磺酰亚胺类衍生物及其应用
KR102605163B1 (ko) * 2021-06-01 2023-11-23 연세대학교 산학협력단 뇌암의 예방 또는 치료용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008066131A1 (en) 2006-12-01 2008-06-05 Banyu Pharmaceutical Co., Ltd. Novel phenyl-isoxazol-3-ol derivative
WO2009147990A1 (ja) 2008-06-02 2009-12-10 萬有製薬株式会社 新規イソオキサゾール誘導体
JP2010519258A (ja) 2007-02-22 2010-06-03 アイアールエム・リミテッド・ライアビリティ・カンパニー Gタンパク質共役受容体のモジュレーターとしてのチアゾール誘導体
JP2014533736A (ja) 2011-11-30 2014-12-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規二環式ジヒドロイソキノリン−1−オン誘導体
JP2016141618A (ja) 2015-01-29 2016-08-08 国立大学法人金沢大学 脱水縮合剤

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2735225A (en) * 1956-02-21 Table ix p petri dish tests with x-phthalimido-
DE2253251A1 (de) 1972-10-30 1974-05-09 Thomae Gmbh Dr K Neue phthalimido-sulfonylharnstoffe
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4165435A (en) * 1976-06-25 1979-08-21 Ciba-Geigy Corporation Fire retardant s-triazine derivatives
EP0145078B1 (en) 1983-12-02 1988-10-12 Shell Internationale Researchmaatschappij B.V. Diphenyl ether herbicides
FR2659327A1 (fr) 1990-03-08 1991-09-13 Centre Nat Rech Scient Derives du benzisothiazolinone-1-dioxyde, utilisables comme inhibiteurs des elastases.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ATE162525T1 (de) 1991-07-30 1998-02-15 Ciba Geigy Ag Heteroaryl substituierte hydroxylaminderivate als lipoxygenase-inhibitoren
US5350761A (en) 1991-07-30 1994-09-27 Ciba-Geigy Corporation Indolyl substituted hydroxylamine derivatives
TW219935B (enExample) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
EP0891332B1 (en) * 1996-03-29 2004-03-17 Pfizer Inc. 6-phenylpyridyl-2-amine derivatives
US6716836B2 (en) 2001-03-22 2004-04-06 Boehringer Ingelheim (Canada) Ltd. Non-nucleoside reverse transcriptase inhibitors
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
EP1688138A4 (en) 2003-11-26 2008-01-16 Takeda Pharmaceutical AGENT FOR REGULATING THE FUNCTION OF A RECEIVER
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N型カルシウムチャネル阻害薬
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
NZ577981A (en) 2006-12-27 2011-12-22 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
AU2008218951B2 (en) 2007-02-22 2011-11-17 Irm Llc Compounds and methods for modulating g protein-coupled receptors
US8318781B2 (en) 2007-04-26 2012-11-27 Japan Science And Technology Agency G-protein-conjugated receptor agonist
US8569378B2 (en) 2007-07-20 2013-10-29 Toshiyuki Sakai p27 protein inducer
CA2740366A1 (en) 2008-10-21 2010-04-29 Metabolex, Inc. Aryl gpr120 receptor agonists and uses thereof
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8362052B2 (en) 2009-03-11 2013-01-29 Msd K.K. Isoindolin-1-one derivative
US8314120B2 (en) 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
CA2801182A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
EP2731944A1 (en) 2011-07-15 2014-05-21 Pfizer Inc Gpr 119 modulators
WO2013139341A1 (en) 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
RU2015116540A (ru) 2012-10-11 2016-12-10 Мерк Шарп И Доум Корп. Замещенные соединения спиропиперидинила, применяемые в качестве агонистов gpr120
KR101942752B1 (ko) 2012-11-05 2019-01-28 주식회사 엘지화학 Gpr120 효능제로서의 티오아릴 유도체
CA2893239A1 (en) 2012-12-03 2014-06-12 F. Hoffmann-La Roche Ag Substituted triazole and imidazole compounds
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
AU2014237600B2 (en) 2013-03-14 2018-03-22 Janssen Pharmaceutica Nv Bicyclic pyrrole derivatives useful as agonists of GPR120
JP6336561B2 (ja) 2013-03-14 2018-06-06 ヤンセン ファーマシューティカ エヌ.ベー. Ii型糖尿病を処置するためのgpr120アゴニスト
US8962660B2 (en) 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators
WO2014159061A2 (en) 2013-03-14 2014-10-02 Janssen Pharmaceutica Nv Benzo-fused heterocyclic derivatives useful as agonists of gpr120
EA201591795A1 (ru) 2013-03-14 2015-12-30 Бристол-Майерс Сквибб Компани Бицикло[2.2.1]-кислоты в качестве модуляторов рецептора gpr120
DK3013796T3 (da) * 2013-06-27 2020-03-16 Lg Chemical Ltd Biarylderivater som gpr120-agonister
AR099937A1 (es) * 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
BR112016024936A2 (pt) 2014-05-07 2017-08-15 Bristol Myers Squibb Co moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
CN107074817B (zh) 2014-08-29 2023-12-15 Chdi基金会股份有限公司 用于成像亨廷顿蛋白的探针
US10457669B2 (en) 2015-10-21 2019-10-29 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
JP7086942B2 (ja) * 2016-09-12 2022-06-20 インテグラル ヘルス, インコーポレイテッド Gpr120モジュレーターとして有用な単環式化合物
CA3041038A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Bicyclic compounds useful as gpr120 modulators

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008066131A1 (en) 2006-12-01 2008-06-05 Banyu Pharmaceutical Co., Ltd. Novel phenyl-isoxazol-3-ol derivative
JP2010519258A (ja) 2007-02-22 2010-06-03 アイアールエム・リミテッド・ライアビリティ・カンパニー Gタンパク質共役受容体のモジュレーターとしてのチアゾール誘導体
WO2009147990A1 (ja) 2008-06-02 2009-12-10 萬有製薬株式会社 新規イソオキサゾール誘導体
JP2014533736A (ja) 2011-11-30 2014-12-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規二環式ジヒドロイソキノリン−1−オン誘導体
JP2016141618A (ja) 2015-01-29 2016-08-08 国立大学法人金沢大学 脱水縮合剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Archiv der Pharmazie,2016年,349(3),P.175-185,(2016年1月13日)
REGISTRY(STN)[online],2011.10.07~2016.06.20[検索日2021.03.01],CAS登録番号1935530-23-6, 1440520-62-6, 1334634-35-3

Also Published As

Publication number Publication date
WO2018049324A1 (en) 2018-03-15
CN110225752A (zh) 2019-09-10
US10800773B2 (en) 2020-10-13
US20230183231A1 (en) 2023-06-15
US12116362B2 (en) 2024-10-15
US20190202821A1 (en) 2019-07-04
CN110225752B (zh) 2023-05-05
KR102537985B1 (ko) 2023-05-30
US20210101896A1 (en) 2021-04-08
CA3041033A1 (en) 2018-03-15
EP3509587A1 (en) 2019-07-17
EP3509587C0 (en) 2023-12-06
EP3509587B1 (en) 2023-12-06
KR20190067174A (ko) 2019-06-14
EP3509587A4 (en) 2020-03-11
JP2019530674A (ja) 2019-10-24
US11548886B2 (en) 2023-01-10

Similar Documents

Publication Publication Date Title
JP7086942B2 (ja) Gpr120モジュレーターとして有用な単環式化合物
JP7065081B2 (ja) Gpr120モジュレーターとして有用な二環式化合物
US20070149547A1 (en) Bipyridyl amides as modulators of metabotropic glutamate receptor-5
JP2009533410A (ja) Gタンパク質共役型受容体(gpr119)アゴニストとしてのアゼチジン誘導体
US10369146B2 (en) Phenyl linked quinolinyl modulators of RORγt
KR20150070348A (ko) RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
CN116438174B (zh) 化合物及其作为mif抑制剂的用途
US20250179017A1 (en) Carboxamide compounds as pge2 receptor antagonists
TW202239416A (zh) 含硼之吡唑化合物、包含彼等之組合物及其方法及用途
KR20160068948A (ko) RORyt의 이차 알코올 퀴놀리닐 조절제
HK40005332A (en) Monocyclic compounds useful as gpr120 modulators
HK40005332B (en) Monocyclic compounds useful as gpr120 modulators
KR20230061482A (ko) 인터페론 유전자 자극제 (stimulator of interferon genes)(STING) 의 작용제들
AU2021301444A1 (en) Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof
HK40005335B (en) Bicyclic compounds useful as gpr120 modulators
HK40005335A (en) Bicyclic compounds useful as gpr120 modulators
EP3057950B1 (en) Phenyl linked quinolinyl modulators of ror-gamma-t

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220520

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220608

R150 Certificate of patent or registration of utility model

Ref document number: 7086942

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250